On August 24, Panlong Pharmaceutical released its 2022 interim report, which showed that it achieved revenue of 431 million yuan in the first half of the year, an increase of 7.
33% year-on-year; Net profit was 45.
6218 million yuan, an increase of 6.
35%
year-on-year.
On August 23, Cr Resources Sanjiu released the first half of the performance report showing that during the reporting period, the company achieved revenue of 8.
401 billion yuan, an increase of 6.
82% year-on-year; Net profit was 1.
449 billion yuan, an increase of 4.
31%
year-on-year.
On August 20, The news of East Ejiao disclosed the semi-annual report of 2022, and the company achieved operating income of 1.
826 billion yuan in the first half of the year, an increase of 8.
25% year-on-year; Achieved a net profit attributable to shareholders of the listed company of 308 million yuan, an increase of 106%
year-on-year.
On the evening of August 19, Baiyun Mountain disclosed its semi-annual report, and the company achieved operating income of 37.
220 billion yuan in the first half of the year, an increase of 3.
02% year-on-year; Net profit was 2.
59 billion yuan, an increase of 3.
5%
year-on-year.
.
.
.
.
.
.
According to incomplete statistics, as of August 25, more than 30 Chinese medicine companies in A-shares have disclosed semi-annual reports, of which more than 60% of net profits have increased
.
And from the perspective of net profit growth, the net profit of more than 10 Chinese medicine enterprises in the first half of the year increased by more than 10%
year-on-year.
Among them, the net profit growth rate is the East Ejiao, the company's net profit in the first half of the year increased by 106% year-on-year, the reason for the performance growth is: the company solidly promoted the "14th Five-Year Plan" strategic planning, closely followed the consumer demand as the core of the strategic main line, and constantly optimized the product structure, upgraded the product portfolio; Deeply practice the customer-centric digital operation model, deepen the extension and expansion of categories and innovative exploration, and achieve customer growth and performance improvement
.
For the performance of East Ejiao, Southwest Securities said in the research report that the company's three main products are ejiao blocks, compound ejiao paste and peach blossom ejiao cake products are strong and are expected to continue to maintain rapid growth
in the future.
This was followed by Jiaying Pharmaceutical, which achieved a net profit attributable to shareholders of listed companies of 8.
5947 million yuan from January to June 2022, an increase of 105.
33%
year-on-year.
It is reported that during the reporting period, the company closely focused on the company's annual work plan, opened a new journey to promote the company's high-quality development, the company's operations as a whole maintained a stable and healthy development, production work steadily, marketing orderly promotion
.
In addition, the performance of the film zai is also more eye-catching, the company's disclosure of the 2022 semi-annual report shows that in the first half of 2022, to achieve revenue of 4.
423 billion yuan, an increase of 14.
91%; Attributable net profit was 1.
314 billion yuan, an increase of 17.
85%
year-on-year.
It is worth mentioning that Chinese medicine enterprises are facing challenges
in terms of cost increase and price decline.
For example, the net profit of the good news in the second quarter of the film Zai Zhen fell in a single quarter, which was related to the increase in costs
.
According to the financial report data, in the first half of 2022, the gross profit margin of the drug for tablets and liver diseases decreased by 0.
4% compared with the same period last year, and the gross profit margin of cardiovascular and cerebrovascular drugs decreased by 3.
33%
compared with the same period last year.
It is understood that in the first half of this year, the main ingredients of the products of The Tablets and Huang Pills of Angong Arenagis and the main ingredients such as natural musk and natural Bovine Yolk are more obvious, or affect the company's net profit level
.
A number of companies also mentioned the price reduction and cost control risks
brought about by policies such as medical insurance negotiations and collection.
For example, Jiaying Pharmaceutical mentioned that due to the implementation of the new version of the medical insurance catalogue and the comprehensive promotion of policies such as consistency evaluation, separation of medicines, and procurement of quantities in recent years, the state has continued to strengthen its control over drug prices, and drug prices have generally shown a downward trend; At the same time, the main material of the products produced by the company is Chinese herbal medicine, which is susceptible to natural disasters or cyclical production reductions and other factors, resulting in some medicinal materials rising in price in a certain period of time, affecting the cost of the product to a certain extent, and the company will also increase
the marketing cost of the product in order to achieve the established benefits.
Looking forward to the future market, many securities believe that the performance of the Chinese medicine sector is obviously differentiated, and in the medium and long term, "policy + pharmaceutical consumption rigidity + stable performance + valuation advantage" jointly construct investment opportunities
in the Chinese medicine industry.
